<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schmidt ME</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>3234-3245</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6529240</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>202(11)</volume><pubmed_abstract>Respiratory syncytial virus (RSV) is the leading cause of severe respiratory tract infection in infants and young children, but no vaccine is currently available. Live-attenuated vaccines represent an attractive immunization approach; however, balancing attenuation while retaining sufficient immunogenicity and efficacy has prevented the successful development of such a vaccine. Recently, a recombinant RSV strain lacking the gene that encodes the matrix (M) protein (RSV M-null) was developed. The M protein is required for virion assembly following infection of a host cell but is not necessary for either genome replication or gene expression. Therefore, infection with RSV M-null produces all viral proteins except M but does not generate infectious virus progeny, resulting in a single-cycle i</pubmed_abstract><journal>Journal of immunology (Baltimore, Md. : 1950)</journal><pubmed_title>Vaccination with a Single-Cycle Respiratory Syncytial Virus Is Immunogenic and Protective in Mice.</pubmed_title><pmcid>PMC6529240</pmcid><funding_grant_id>P20 GM103648</funding_grant_id><funding_grant_id>R01 AI124093</funding_grant_id><funding_grant_id>T32 AI007485</funding_grant_id><funding_grant_id>P30 CA086862</funding_grant_id><pubmed_authors>Oomens AGP</pubmed_authors><pubmed_authors>Varga SM</pubmed_authors><pubmed_authors>Schmidt ME</pubmed_authors></additional><is_claimable>false</is_claimable><name>Vaccination with a Single-Cycle Respiratory Syncytial Virus Is Immunogenic and Protective in Mice.</name><description>Respiratory syncytial virus (RSV) is the leading cause of severe respiratory tract infection in infants and young children, but no vaccine is currently available. Live-attenuated vaccines represent an attractive immunization approach; however, balancing attenuation while retaining sufficient immunogenicity and efficacy has prevented the successful development of such a vaccine. Recently, a recombinant RSV strain lacking the gene that encodes the matrix (M) protein (RSV M-null) was developed. The M protein is required for virion assembly following infection of a host cell but is not necessary for either genome replication or gene expression. Therefore, infection with RSV M-null produces all viral proteins except M but does not generate infectious virus progeny, resulting in a single-cycle i</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jun</publication><modification>2025-04-04T14:00:25.157Z</modification><creation>2020-06-04T07:05:09Z</creation></dates><accession>S-EPMC6529240</accession><cross_references><pubmed>31004010</pubmed><doi>10.4049/jimmunol.1900050</doi></cross_references></HashMap>